<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">Maternal vaccination appears to be the most direct and optimal strategy to prevent early RSV disease in most neonates and young infants. This strategy is supported by the following observations:
 <list list-type="simple" id="l0010">
  <list-item id="u0010">
   <label>•</label>
   <p id="p0080">Maternal RSV infection prior to delivery correlates with decreased incidence of RSV bronchiolitis in infants.</p>
  </list-item>
  <list-item id="u0015">
   <label>•</label>
   <p id="p0085">Higher concentrations of RSV-specific maternally-derived antibody at birth are associated with lower incidence and later onset of RSV disease in neonates during the first months of life.</p>
  </list-item>
  <list-item id="u0020">
   <label>•</label>
   <p id="p0090">Passive anti-F IgG (e.g. Palivizumab) administration reduces the incidence of severe RSV disease.</p>
  </list-item>
  <list-item id="u0025">
   <label>•</label>
   <p id="p0095">Pregnant women are primed for RSV from previous infections and vaccination will boost their antibodies, achieving higher concentrations at a time when active antibody transfer mechanisms in the placenta favor the passage of antibodies to the fetus.</p>
  </list-item>
  <list-item id="u0030">
   <label>•</label>
   <p id="p0100">Transplacental transfer of RSV-specific IgG from mothers to neonates is highly efficient.</p>
  </list-item>
  <list-item id="u0035">
   <label>•</label>
   <p id="p0105">In addition to transplacental antibody transfer, there is also a potential for protection of lactating infants from RSV-specific breastmilk antibodies (natural and vaccine induced).</p>
  </list-item>
  <list-item id="u0040">
   <label>•</label>
   <p id="p0110">There is a precedent of success of maternal immunization as a strategy for the prevention of maternal and infant tetanus, pertussis, and influenza.</p>
  </list-item>
 </list>
</p>
